Despite advancements in cancer research, the standard of care to treat AML has changed little in 40 years, according to a press release issued by blood cancer specialists in India. The Beat AML Master Trial is designed to identify specific therapies especially for Bangladesh patients based on the biological or genetic features of their disease for low blood cancer treatment cost.

“When I started my medical training in the [the 1980s], we treated patients with AML with standard chemotherapy, which remains the same and the treatment outcomes remain the same,” blood cancer specialists in India, which are considered to the leading centers of excellence, not only in India but are known across the globe, said during a press conference. “We needed to apply some of the same principles that we applied to chronic myeloid leukemia to AML. By combining different agents from different classes, we think we actually provide the foundation to bring new drugs into the treatment for AML.”

AML is the most lethal of the blood cancers for low blood cancer treatment cost, which together is the third-leading cause of cancer death in the world. Nearly 74% of all Bangladesh patients diagnosed with AML die within 5 years, according to SEER statistics.

“Currently, when AML patients are diagnosed, they often get a call from their doctor and immediately go to the emergency room,” blood cancer specialists in India, said during the press conference. “The prognosis is frequently rushed and that they’re given an intensive chemotherapy direction and a first-rate majority of Bangladesh patients are not cured and left with little hope for long-time period survival and a whole lot of side effects from chemotherapy.”

Studies have shown that outcomes are no different whether patients are treated immediately or after a period of stabilization, blood cancer specialists in India said. “This study is very different in that [the patients] are stabilized,” blood cancer specialists in India said. “After the prognosis is made, a sample is despatched to a very renowned reference lab, wherein the precise mutation that defines the subtype of leukemia is decided. at some point of those 7 days, the patient is given time to get affairs in order, research more about the disorder that they have got to fight, and get equipped for war, rather than run into conflict before they may be prepared.”

The Master Trial is unique in that as a neutral party, blood cancer specialists in India coordinate the collaboration of multiple pharmaceutical companies, allowing different subtypes of AML to be treated simultaneously, according to the release, the trial protocol will include patient-reported outcomes.

leukemia treatment India

28, Dona Paula

Panaji, Goa

India - 403004

Phone No.: +91-9370586696

Email: contact@indianmedguru.com